255 related articles for article (PubMed ID: 32160544)
1. Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling.
Day EK; Sosale NG; Xiao A; Zhong Q; Purow B; Lazzara MJ
Cell Rep; 2020 Mar; 30(10):3383-3396.e7. PubMed ID: 32160544
[TBL] [Abstract][Full Text] [Related]
2. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
3. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
[TBL] [Abstract][Full Text] [Related]
4. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
Walsh AM; Lazzara MJ
J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
[TBL] [Abstract][Full Text] [Related]
5. Sprouty2 enhances the tumorigenic potential of glioblastoma cells.
Park JW; Wollmann G; Urbiola C; Fogli B; Florio T; Geley S; Klimaschewski L
Neuro Oncol; 2018 Jul; 20(8):1044-1054. PubMed ID: 29635363
[TBL] [Abstract][Full Text] [Related]
6. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Wu DW; Wang YC; Wang L; Chen CY; Lee H
Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
[No Abstract] [Full Text] [Related]
7. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
[TBL] [Abstract][Full Text] [Related]
8. Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.
Ding W; Shi W; Bellusci S; Groffen J; Heisterkamp N; Minoo P; Warburton D
J Cell Physiol; 2007 Sep; 212(3):796-806. PubMed ID: 17516543
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
11. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
Fukuoka M; Yoshioka K; Hohjoh H
PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.
Zanca C; Villa GR; Benitez JA; Thorne AH; Koga T; D'Antonio M; Ikegami S; Ma J; Boyer AD; Banisadr A; Jameson NM; Parisian AD; Eliseeva OV; Barnabe GF; Liu F; Wu S; Yang H; Wykosky J; Frazer KA; Verkhusha VV; Isaguliants MG; Weiss WA; Gahman TC; Shiau AK; Chen CC; Mischel PS; Cavenee WK; Furnari FB
Genes Dev; 2017 Jun; 31(12):1212-1227. PubMed ID: 28724615
[TBL] [Abstract][Full Text] [Related]
13. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Xu L; Meng X; Xu N; Fu W; Tan H; Zhang L; Zhou Q; Qian J; Tu S; Li X; Lao Y; Xu H
Cell Death Dis; 2018 Feb; 9(3):262. PubMed ID: 29449529
[TBL] [Abstract][Full Text] [Related]
14. Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream of receptor tyrosine kinase signaling.
Chandramouli S; Yu CY; Yusoff P; Lao DH; Leong HF; Mizuno K; Guy GR
J Biol Chem; 2008 Jan; 283(3):1679-1691. PubMed ID: 17974561
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
17. Direct binding of PP2A to Sprouty2 and phosphorylation changes are a prerequisite for ERK inhibition downstream of fibroblast growth factor receptor stimulation.
Lao DH; Yusoff P; Chandramouli S; Philp RJ; Fong CW; Jackson RA; Saw TY; Yu CY; Guy GR
J Biol Chem; 2007 Mar; 282(12):9117-26. PubMed ID: 17255109
[TBL] [Abstract][Full Text] [Related]
18. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
19. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.
Yang W; Xia Y; Cao Y; Zheng Y; Bu W; Zhang L; You MJ; Koh MY; Cote G; Aldape K; Li Y; Verma IM; Chiao PJ; Lu Z
Mol Cell; 2012 Dec; 48(5):771-84. PubMed ID: 23123196
[TBL] [Abstract][Full Text] [Related]
20. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]